Rodman & Renshaw Initiates Coverage on Cerecor Inc(NASDAQ:CERC). The shares have been rated Buy. The rating by Rodman & Renshaw was issued on Apr 13, 2016.
Several Insider Transactions has been reported to the SEC. On Oct 20, 2015, Ronald Marcus (Chief Medical Officer) purchased 30,617 shares at $0.00 per share price.
Cerecor Inc. (Cerecor) is a United States-based biopharmaceutical company. The Company is developing treatments for patients suffering from nervous system disorders. CERC-301 is a potent and selective NR2B antagonist. Cerecor specializes in developing drugs to treat neuropsychological disorders such as anxiety and depression. Cerecor is focused on translational medicine. It is focused on the discovery development and commercialization of prescription pharmaceuticals whose primary activity is in the human brain.